Alpha emitter radium 223 in high-risk osteosarcoma: First clinical evidence of response and blood-brain barrier penetration

JAMA Oncology

Volumn 1, Issue 2, 2015, Pages 253-255

  Subbiah, Vivek ^a   Anderson, Pete ^b   Rohren, Eric ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Levine Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM; RADIUM CHLORIDE RA 223;

ADULT; BLOOD BRAIN BARRIER; BRAIN NEOPLASMS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMORAL NEOPLASMS; HUMAN; MALE; METABOLISM; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PATHOLOGY; PERMEABILITY; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SECONDARY; TIME; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADULT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; FEMORAL NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; OSTEOSARCOMA; PERMEABILITY; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84965092181     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2014.289     Document Type: Letter

References (6)

1. Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol. 2014;804:291-304.
2. Parker C, Nilsson S, Heinrich D, et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369 (3):213-223.
3. Kluetz PG, Pierce W, Maher VE, et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2014;20(1):9-14.
4. Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20, pt 2): 6250s-6257s.
5. Jahnke K, Doolittle ND, Muldoon LL, Neuwelt EA. Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus. 2006;21(5):E11.
6. Doolittle ND, Jahnke K, Belanger R, et al. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.Leuk Lymphoma. 2007;48(9):1712-1720.